Key facts
- This page summarizes Harald Reinhart's Form 4 filing for Zai Lab Ltd (ZLAB).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 03 Jan 2024, 19:25.
Harald Reinhart - 01 Jan 2024 Form 4 Insider Report for Zai Lab Ltd (ZLAB)
- Reporting relationship
- President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases
- Issuer ticker
- ZLAB
- Reported as of
- 01 Jan 2024
- Net transaction value
- -$125,464
- SEC form
- 4
- Accepted by SEC
- 03 Jan 2024, 19:25:23 UTC
- Prior SEC filing
- 26 Jun 2023
- Next SEC filing
- 03 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Bruce Blefeld, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Harald Reinhart filed Form 4 for Zai Lab Ltd (ZLAB) on 03 Jan 2024.
Change
- Previous filing in this sequence was filed on 26 Jun 2023.
- Current net transaction value: -$125,464.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZLAB
transaction
American Depositary Shares
Options Exercise
- Transaction value
- Shares
- +17,548
- Change %
- +53%
- Price
- Shares after
- 50,863
- Date
- 01 Jan 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F3
ZLAB
transaction
American Depositary Shares
Sale
- Transaction value
- $125,464
- Shares
- -4,803
- Change %
- -9.4%
- Price
- $26.12
- Shares after
- 46,060
- Date
- 03 Jan 2024
- Ownership
- Direct
- Footnotes
- F1, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZLAB
transaction
Derivative
Performance-Based Share Units
Award
- Transaction value
- $0
- Shares
- +17,548
- Change %
- Price
- $0.000000
- Shares after
- 17,548
- Date
- 01 Jan 2024
- Ownership
- Direct
- Underlying class
- American Depositary Shares
- Underlying amount
- 17,548
- Exercise price
- Footnotes
- F1, F3, F5
ZLAB
transaction
Derivative
Performance-Based Share Units
Options Exercise
- Transaction value
- $0
- Shares
- -17,548
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Jan 2024
- Ownership
- Direct
- Underlying class
- American Depositary Shares
- Underlying amount
- 17,548
- Exercise price
- Footnotes
- F1, F3, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
Footnote F2
ADSs acquired on vesting of performance-based share units (PSUs). Each ADS represents ten Ordinary Shares of the issuer.
Footnote F3
Each PSU represents a contingent right to receive one ADS, which represents ten Ordinary Shares of the issuer.
Footnote F4
These ADSs were sold automatically to cover taxes upon vesting of PSUs.
Footnote F5
The reporting person was granted PSUs on December 1, 2021 that vest based on the satisfaction of specified performance criteria between December 1, 2021 and December 31, 2025. On January 1, 2024, the performance-based vesting conditions were confirmed for PSUs representing 17,548 ADSs.
SEC remarks
President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases